Monitor upcoming clinical readouts for ABCL635 (expected Q3 2026) and ABCL575 (H2 2026), as these could be significant catalysts. The company's strong liquidity position suggests it can fund operations for several years without immediate need for dilution.
Price Chart
Executive Summary
AbCellera reported strong financial results for 2025, with revenue nearly tripling to $75.1 million and net loss narrowing to $146.4 million from $162.9 million in 2024. The company successfully transitioned to a clinical-stage biotech, advanced key programs into clinical trials, and ended the year with $700 million in liquidity. This represents significant operational progress and improved financial performance.
Key Financial Metrics
Key Facts
- Revenue increased 160% year-over-year to $75.1 million
- Net loss decreased from $162.9 million in 2024 to $146.4 million in 2025
- Net loss per share improved from $(0.55) to $(0.49)
- Advanced two programs (ABCL635 and ABCL575) into clinical trials
- Ended 2025 with approximately $700 million in available liquidity
- Partner-initiated program starts increased from 96 to 104 (8% growth)
- Molecules in the clinic increased from 16 to 19 (19% growth)
Financial Impact
Revenue grew from $28.8M to $75.1M (160% YoY increase), while net loss narrowed from $162.9M to $146.4M
Risk Factors
- Continued net losses despite revenue growth
- Dependence on successful clinical trial outcomes for future value creation
- High R&D expenses ($186.8M) relative to revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001703057-26-000010 |
| Document: abcl-20260224.htm | 0001703057-26-000010 |
| Document: a2025q4fybusinessupdatef.htm | 0001703057-26-000010 |
| Document: 0001703057-26-000010-index-headers.html | 0001703057-26-000010 |
| Document: 0001703057-26-000010-index.html | 0001703057-26-000010 |
| Document: 0001703057-26-000010.txt | 0001703057-26-000010 |
| CONTEXT: Previous Earnings (2026-02-24) | 0001703057-26-000010 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | Insider Cluster | $10.61 $12.65 | ▲ +19.23% | ▲ +17.91% | $13.74 (+29.50%) |
Aug 18, 2026 6w ago | Insider Cluster | $11.12 $11.67 | ▲ +4.95% | ▲ +6.69% | $13.74 (+23.56%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.20 $11.41 | ▼ −1.88% | ▼ −3.85% | $13.74 (−22.68%) |
Aug 11, 2026 7w ago | 424B5 | $10.36 $10.46 | ▼ −1.01% | ▼ −2.91% | $13.74 (−32.69%) |
Aug 10, 2026 7w ago | 8-K | $9.34 $11.44 | ▲ +22.48% | ▲ +23.40% | $13.74 (+47.11%) |
Jul 29, 2026 9w ago | 8-K | $5.39 $12.24 | ▲ +127.09% | ▲ +122.07% | $13.74 (+154.92%) |
Jul 6, 2026 12w ago | 3 | $7.69 $5.83 | ▼ −24.19% | ▼ −25.52% | $13.74 (+78.67%) |
Jul 6, 2026 12w ago | 8-K | $7.87 $5.71 | ▼ −27.45% | ▼ −26.88% | $13.74 (+74.59%) |
Jun 5, 2026 17w ago | 8-K | $5.62 $7.87 | ▲ +40.04% | ▲ +38.17% | $13.74 (+144.48%) |
May 11, 2026 20w ago | 8-K | $4.95 $5.09 | ▲ +2.83% | ▲ +4.56% | $13.74 (+177.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access